Stroop-CN: A rapid diagnostic tool for minimal hepatic encephalopathy

This study is led by Dr. Xiaolong Qi (Center of Portal Hypertension, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology) and Dr. Junliang Fu (Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases). Based on a nationwide, multicenter study, the team presented a diagnosis model named Stroop-CN. Through their model, minimal hepatic encephalopathy (MHE) could be confirmed in 10 min.

"The initial aim is how could we help patients before it is too late.", says Dr. Fu. As one of the crucial comorbidities, hepatic encephalopathy occurs in 50-80% of cirrhotic patients and leads to high mortality. Therefore, MHE, the early phase of hepatic encephalopathy, characterized by neuropsychological disorders without behavioral abnormalities, plays an essential role in early intervention. While studies have demonstrated that MHE significantly reduces patient survival and can be reversed, the insidious nature of the disease and the complexity of traditional pen-and-paper experiments continue to straddle both patients and physicians. The group tried various diagnostic tools, with the Stroop test attracting their attention because of its user-friendliness. However, the team immediately realized that individual information such as age and education can lead to changes in diagnostic thresholds. So, the next question they faced was, how to use this software for rapid MHE diagnosis? 

In this study, they chose to synchronize the results of a large-scale collection of healthy controls to create the "Stroop-CN" model. Based on this model, information such as the age of the subjects was submitted to help determine whether the patient's cognitive level was lower than that of their healthy counterparts. On the other hand, the corresponding time, financial, and workload burdens must also be considered.

Time and speed are also important. We have to take it into consideration, especially in China, where one of the fifth patients got a liver problem." 

Dr. Xiaolong Qi, Center of Portal Hypertension, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology

Using the Stroop-CN model, their slowest-operating MHE patients completed the tests in less than 5 min.

One of the reasons that medicine still does not pay enough attention to MHE is the complexity of the diagnosis. This paper uses a simple Stroop test to build a diagnostic model that can be applied even to subjects who can only identify colors and a few words. Further, MHE was found in nearly half of the patients with cirrhosis accompanied by reduced QOL. These evidences would apply to cirrhotic patients in China and, to some extent, provide a reference for exploring a generally applicable diagnostic and monitoring method for MHE.

Source:
Journal reference:

Li, X., et al. (2024). Detection of minimal hepatic encephalopathy in patients with cirrhosis based on the Stroop‐CN model (NCRCID‐CHESS 2106): a prospective multicenter study. MedComm. doi.org/10.1002/mco2.627.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug approach shows promise in treating metabolic liver diseases